Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514939 | 1.00 | SOS1 (0.67) | SOS1NPC1MAPTRAB9ALMNA | |
| Trifluoroacetic Acid SCHEMBL30040872 | 0.88 | SOS1 (0.54) | SOS1NPC1MAPTRAB9ASIGMAR1 | |
| SCHEMBL5633385 | 0.83 | NPC1 (0.54) | SOS1NPC1MAPTRAB9ALMNA | |
| SCHEMBL23932531 | 0.81 | SOS1 (0.62) | SOS1LMNATP53SIGMAR1 | |
| SCHEMBL4908138 | 0.80 | NPC1 (0.47) | SOS1NPC1MAPTRAB9ALMNA | |
| SCHEMBL14432506 | 0.78 | SOS1 (0.58) | SOS1LMNADRD3DRD2 | |
| SCHEMBL9933061 | 0.77 | NPC1 (0.44) | SOS1NPC1MAPTRAB9ALMNA | |
| SCHEMBL23964195 | 0.76 | DRD3 (0.60) | NPC1MAPTRAB9ALMNASMN1; SMN2 | |
| SCHEMBL10566155 | 0.75 | DRD3 (0.60) | NPC1MAPTRAB9ASMN1; SMN2DRD3 | |
| SCHEMBL23964197 | 0.75 | DRD3 (0.47) | SOS1NPC1MAPTRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-07-24 | — | — | US | disclosed |
| US-7091219-B2 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-6384036-B1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176842-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | PRSS1, DNPEP, PREP | SOS1 434/4885NPC1 2193/4885MAPT 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.